R-CHOP, R-CVP Confer Favorable Outcomes in Follicular Lymphoma

Share this content:
The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.
The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.

A long-term post-hoc analysis of the FOLL05 trial (ClinicalTrials.gov Identifier: NCT00774826) confirmed that rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab plus cyclophosphamide, vincristine, and prednisone (R-CVP) resulted in favorable outcomes compared with rituximab plus fludarabine and mitoxantrone (R-FM) among patients with advanced-stage symptomatic follicular lymphoma (FL).

The previous analysis demonstrated that R-CHOP and R-CVP were superior to R-FM, though R-CHOP was associated with less toxicity than R-CVP after a median of 34 months of follow-up. The purpose of this post hoc analysis was to determine the long-term efficacy and safety of the 3 regimens after a median of 84 months of follow-up.

The open-label, multicenter, phase 3 FOLL05 trial included untreated patients with grade 1, 2, or 3a and Ann Arbor stage II to IV disease. This analysis included 504 evaluable patients.

The overall rates of progression-free survival (PFS) were similar among the arms. When, however, PFS was adjusted by the FL International Prognostic Index 2, R-CHOP resulted in a significant improvement in PFS compared with R-CVP (hazard ratio [HR], 0.73; 95% CI, 0.54-0.98; P = .037) and R-FM (HR, 0.67; 95% CI, 0.50-0.91; P = .009).

Time to treatment failure (TTF) was longer with R-CHOP (45%; HR, 0.73; 95% CI, 0.55-0.98; P = .033) and R-CVP (49%; HR, 0.70; 95% CI, 0.52-0.93; P = .016) compared with R-FM.

There was no significant difference in overall survival among the 3 arms, with an 8-year rate of 83% (95% CI, 79%-87%).

Secondary malignancies occurred in 9.4% of patients overall, with the highest proportion occurring in the R-CHOP arm (12%; 95% CI, 7.7%-18.7%) followed by the R-FM (9.6%; 95% CI, 6.0%-15.2%) and the R-CVP (6.2%; 95% CI, 2.5%-14.8%) arms.

The authors wrote that “[i]f the initial aim is to maximize treatment activity and increase the chance of durable disease control, R-CHOP should be the preferred option.” They added, however, that R-CVP is also a good option, particularly among patients whose goal for therapy is tolerability.

Reference

  1. Luminari S, Ferrari A, Manni M, et al. Long-term results of the FOLL05 trial comparing R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage symptomatic follicular lymphoma. J Clin Oncol. 2017 Nov 2. doi: 10.1200/JCO.2017.74.1652 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters